Metastatic non-seminomatous testis tumors: morbidity of treatment.
There were 28 patients with metastatic non-seminomatous testis tumors treated by a regimen of combined retroperitoneal lymphadenectomy and multiple drug chemotherapy. We have outlined the morbidity of this plan of management with a followup of 3 to 8 years. Survival for all patients with stage B disease is 100 per cent and with stage C disease it is 58 per cent (8 of 14 patients).
D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D008197:Lymph Node Excision; D008207:Lymphatic Metastasis; D008297:Male; D009367:Neoplasm Staging; D011183:Postoperative Complications; D011788:Quality of Life; D012186:Retroperitoneal Neoplasms / Q000556:secondary* / Q000628:therapy; D013736:Testicular Neoplasms / Q000628:therapy*
D000970:Antineoplastic Agents